1. Introduction {#sec1}
===============

The gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols with either highly purified human menopausal gonadotropin (HP-hMG) or recombinant FSH (rFSH) preparations are the most widely used protocols for controlled ovarian stimulation (COS) for both intracytoplasmic sperm injection (ICSI) and *in vitro* fertilization (IVF) \[[@B1]--[@B3]\]. At present, most of the mature oocytes retrieved after COS are capable of fertilization; however, only half of them develop into good embryos and only a few implants. There is increasing evidence that cumulus cells (CCs), which are somatic cells that surround the oocyte, play a crucial role in folliculogenesis and oocyte developmental competence acquisition \[[@B4], [@B5]\]. Several authors propose the use of CC gene expression as a noninvasive approach to predict oocyte aneuploidy, and oocyte competence, as well as embryo and pregnancy outcomes during assisted reproductive technology (ART) procedures \[[@B6]--[@B17]\]. Despite the recent molecular advances in the knowledge of human CCs, our understanding is far from complete. We believe that the characterization of the biology of these cells following COS might explain observed changes in *in vitro* embryo development. Several studies have compared the effects of HP-hMG and rFSH on oocyte and embryo quality, follicular fluid biochemical profile, and pregnancy rate \[[@B18]--[@B23]\]. However, their specific effects on the gene expression profile of individual CC samples have not been investigated. To date, only two such studies have been reported. They compared the gene expression profiles of pooled human granulosa cells (GCs) from periovulatory follicles of six patients in one study and eight patients in the other study. In both studies, the patients were treated with HP-hMG or rFSH in a GnRH agonist long protocol. Significant differences have been observed \[[@B24], [@B25]\]. The aims of the present study were (i) to compare the gene expression profiles of large cohorts of individual CCs isolated from periovulatory follicles of patients stimulated with HP-hMG or rFSH in a GnRH antagonist protocol and (ii) to determine the relationship between *in vitro* embryo development and expression profiles of CCs isolated from mature oocytes after COS.

2. Materials and Methods {#sec2}
========================

2.1. Study Oversight {#sec2.1}
--------------------

This research was approved by our Institutional Review Board. All patients provided their written informed consent for the use of CC samples for research.

2.2. Sample Collection and Treatment Cycle {#sec2.2}
------------------------------------------

This study is a retrospective analysis of data from of a subgroup of eleven randomly selected patients, who participated in an open-label, assessor-blind, parallel groups, multicenter trial (ClinicalTrials.gov Identifier: [NCT00884221](http://clinicaltrials.gov/ctz/results?term=NCT00884221)) that was previously described \[[@B26]\]. CCs (*n* = 146) were collected from all oocytes retrieved from four patients treated with HP-hMG (Menopur, Ferring Pharmaceuticals) and seven patients treated with rFSH (Follitropin beta, Puregon; MSD) following a GnRH antagonist protocol (Ganirelix Acetate, Orgalutran; MSD), respectively. Stimulation with HP-hMG or rFSH was started at a dose of 150 IU/day (first 5 days of the COS protocol), and the patients\' follicular response during stimulation was monitored by transvaginal ultrasound. The GnRH antagonist (daily dose of 0.25 mg) was initiated at day 6 and continued throughout the stimulation period. Transvaginal ultrasound echo guidance, FSH, LH, and estradiol levels were used to monitor the ovarian response. A single injection of 250 *μ*g human chorionic gonadotropin (hCG) (choriogonadotropin alfa, Ovitrelle; Merck Serono) was administered to induce the final follicular maturation when three or more follicles ≥17 mm in diameter were observed. Cumulus-oocyte-complexes were collected 36 h after hCG administration (day 0). Supplemental Table SI (see Supplementary Materials available online at <http://dx.doi.org/10.1155/2013/354582>) shows a summary of the patients\' clinical features, end-of-stimulation data, and the number of retrieved oocytes/patients. All CCs were mechanically removed shortly after oocyte retrieval, washed in culture medium, and frozen immediately prior to total RNA extraction. MII oocytes were used for ICSI. All embryos and blastocysts were assessed daily by the embryologists until 5 days after oocyte retrieval. Embryo quality was assessed at 26 ± 2 and 92 ± 2 hours after insemination. On day 5, the quality evaluations of blastocysts consisted of expansion and hatching status, inner cell mass grading (grade A-C), and trophectoderm grading (grade A-C) \[[@B26]--[@B28]\]. Each CC sample included only CCs from a single oocyte. The number of CCs isolated from oocytes at GV, MI, and MII stages and the *in vitro* embryo outcome for the two patients\' groups (HP-hMG or rFSH) are reported in ([Figure 1](#fig1){ref-type="fig"}).

2.3. Cumulus Cells RNA Extraction {#sec2.3}
---------------------------------

The RNeasy Micro kit (ref. 74004, Qiagen) was used to extract total RNA from each CCs sample (*n* = 146) according to the manufacturers\' recommended protocols. The quantity and purity of the total RNAs were determined by using a NanoDrop ND-1000 spectrophotometer (NanoDrop ND-Thermo Fisher Scientific, Wilmington, DE, USA) and their integrity by using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, <http://www.agilent.com/>). All RNA samples were stored at −80°C until the microarray experiments.

2.4. Preparation of cRNA and Microarray Hybridization {#sec2.4}
-----------------------------------------------------

Total RNA (50 ng) was used to prepare cRNA (one cycle of amplification) using the Affymetrix 3′ IVT express protocol. An oligo-dT primer with a T7 promoter sequence was used to synthesize the first-strand cDNA. After generating the second strand, the complete cDNA was amplified by *in vitro* transcription (linear amplification) with a T7 RNA polymerase. The amplified RNA (aRNA) was generated and quantified by using a NanoDrop ND-1000 spectrophotometer (NanoDrop ND-Thermo Fisher Scientific, Wilmington, DE, USA), and biotinylated nucleotide analog was incorporated during *in vitro* transcription step. RNA from the GeneChip Eukaryotic Poly-A RNA Control Kit (Affymetrix, Santa Clara, CA), which contains mRNAs from *Bacillus subtilis* genes (*lys*, *phe*, *thr*, and *dap*), was amplified and labeled under the same conditions as positive controls. After fragmentation, the labeled antisense aRNA (15 *μ*g) was hybridized to HG-U133 Plus 2.0 GeneChip pan-genomic oligonucleotide arrays (Affymetrix) containing 54,675 sets of oligonucleotide probes (probeset) which correspond to *≈*25,000 unique human genes or predicted genes. Each cumulus cell sample was put individually on a microarray chip. Microarray experiments were performed in DNA microarray platform of our Institute of Research in Biotherapy at the Montpellier University Hospital.

2.5. Data Processing and Gene Expression Profile Analysis {#sec2.5}
---------------------------------------------------------

After image processing with the Affymetrix GeneChip Operating 1.4 software (GCOS), the CEL files were analyzed using the Affymetrix Expression Console Software v1.3.1 and normalized with the MAS5.0 algorithm by scaling each array to a target value (TGT) of 100 using the global scaling method to obtain an intensity value signal for each probe set. This algorithm also determines whether a gene is expressed with a defined confidence level or not ("detection call"). This "call" can either be "present" (when the perfect match probes are significantly more hybridized than the mismatch probes, *P* \< 0.04), "marginal" (for *P* values of \>0.04 and \<0.06) or "absent" (*P* \> 0.06). Gene annotation was performed using NetAffx (<http://www.affymetrix.com/>, March 2009). A first selection of microarray data was based on the detection call (present in at least 50% of the CC samples of each group). Then, the Significant Analysis of Microarrays (SAM) (<http://www-stat.stanford.edu/~tibs/SAM/>) with the Wilcoxon test and sample label permutation (*n* = 300) was used to identify genes of which expression varied significantly between the HP-hMG and rFSH CC samples. The lists of significant genes (fold change, FC ≥1.5 and false discovery rate, FDR ≤5%) as well as common genes were analyzed using the Ingenuity Pathway Analysis (IPA) software (<http://www.ingenuity.com/>) to identify the biological functions that were specific of each CC group and in common between the two treatments, respectively. Only annotations with significant *P* value (*P* \< 0.05) were considered. Then, the SAM analysis (FC ≥1.5, FDR ≤5%) was used to link gonadotropin-specific genes in CCs or those that are irrespective of gonadotropin treatment to subsequent embryo outcome at day 3 (top, good embryo versus poor) or day 5 (good blastocyst versus bad). Hierarchical clustering analyses based on the expression levels of the differentially expressed genes were performed by using the Cluster and Treeview software packages \[[@B29]\]. Box-and-whisker plots depicted the comparisons of the expression levels of candidate genes carried out using SPSS 12.0 (SPSS, Chicago, IL, USA) software.

2.6. Microarray Data Validation by Quantitative RT-PCR {#sec2.6}
------------------------------------------------------

Quantitative RT-PCR was performed to validate the expression of selected genes identified as differentially expressed between the two CC groups by using mRNAs from HP-hMG (*n* = 4) and rFSH (*n* = 4) CC samples as described in \[[@B30]\]. The primer sequences are shown in (Supplementary data, Table SII). Briefly, cDNA was reverse transcribed (RT) following the manufacturer\'s instructions using 500 ng of amplified RNA in a 20 *μ*L reaction volume that included Superscript II (ref. 18064-014, Invitrogen), oligo-dT primer, dNTP mixture, MgCl~2~, and RNase inhibitor. Quantitative PCR was performed using a LightCycler 480 apparatus with the LC480 SYBR Green I Master kit (Roche Diagnostics, Mannheim, Germany) and 2 *μ*L of diluted cDNA (1/25) and 0.6 mMol primers in a total volume of 10 *μ*L. After 10 min of activation at 95°C, cycling conditions were 10 s at 95°C, 30 s at 63°C, and 1 s at 72°C for 45 cycles. Gene expression levels were normalized to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), because its expression was stable between all CC groups using the following formula 100/2^ΔΔCt^, where ΔΔCt = ΔCt unknown  −  ΔCt positive control.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Statistical analyses were performed with SPSS 12.0 software. A repartition difference between sample groups was considered significant when the Kruskal-Wallis nonparametric test and Wilcoxon test gave a *P* value ≤0.05. For q-RT-PCR, a statistical analysis was performed with the GraphPad InStat software (Mann-Whitney *U* test; GraphPad, San Diego, CA). A value of *P* ≤ 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Identification of Differentially Expressed Genes in Human CCs following Stimulation with HP-hMG or rFSH {#sec3.1}
------------------------------------------------------------------------------------------------------------

A first selection is based on the detection call between all the CC samples from patients stimulated with HP-hMG or rFSH delineated 9,899 genes. Then, using SAM, 94 genes that significantly differentiated between HP-hMG and rFSH CCs were identified. Among them, 45 and 49 genes were upregulated in HP-hMG and rFSH CC samples, respectively (fold-change, FDR, and annotation are in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). The HP-hMG CC list included genes implicated in lipid metabolism such as *GM2A*(x2.3, FDR = 0), *AKR1C1* (x1.5, FDR = 0), *AKR1C2* (x1.6, FDR = 0.005), and in cell-to-cell interaction like *GJA5* (x1.9, FDR = 0), *NTS*(x1.8, FDR = 0.005), *FOS* (x1.6, FDR = 0), and*NPY1R*(x2.1, FDR = 0), *NPY2R*(x1.6, FDR = 0). Conversely, the rFSH CC list was significantly enriched in genes important for cellular assembly and organization such as *COL3A1* (x2, FDR = 0.015), *COL1A1* (x1.5; FDR = 0), *MT3* (x1.5; FDR = 0), and *CAMK1D* (x1.5; FDR = 0). Other genes of the rFSH list are members of the tumour necrosis factor (*TNF*) family such as *TNFAIP6* (x1.7; FDR = 0.01) and *TNFAIP8*(x1.6, FDR = 0.005). The clustering based on these 94 genes segregates the majority of the HP-hMG (85%) from the rFSH CC samples ([Figure 2](#fig2){ref-type="fig"}). RT-qPCR validated the differential expression of some of these genes (Supplementary data, Figure SI).

3.2. Common Transcriptional Gene Profile in HP-hMG/rFSH CCs {#sec3.2}
-----------------------------------------------------------

In view of few differences between the two gonadotropin treatments, we examined the list of genes in common to HP-hMG and rFSH groups (list of 9,805 genes; see Supplementary data, Table SIII). We used IPA software to explore the specific functional properties of this common molecular signature. Estrogen receptor signaling (83 genes) (*P* value = 8.17*E* − 08) was one of the top canonical pathways related to this molecular signature. On the other hand, the top network involving 35 genes was articulated around the "cell death and survival, DNA replication, recombination, and repair" functions. The detailed list of genes involved in this network can be found in (Supplementary data, Table SIV). Interestingly, the most common HP-hMG/rFSH genes were associated with multiple signaling pathways including *FGF* signaling (*FGFR and GRB2*), *IGF* signaling (*IGF1R* and *IGFBP3*), *EGF* signaling (*EGFR* and *MAPK1*), and *PDGF* signaling (*PDGFRA* and *PDGFD*). It is important to note that no difference was observed in the mRNA CC level between treatments for receptors (*LHCGR* and *BMPR2*), aromatase (*CYP19A1*), cytochrome *P450* (*CYP11A1*), or steroidogenic genes (*StAR*, *HSD3B2*, *ACVR1*, *ACVR1B*, *INHBC*, and *INHBB*).

3.3. Relationship between the HP-hMG or rFSH CC Expression Profiles and **In Vitro** Embryo Development {#sec3.3}
-------------------------------------------------------------------------------------------------------

Of the 146 CC samples, 101 were isolated from MII mature oocytes which underwent ICSI. In the HP-hMG group, 77% of injected oocytes were fertilized and 61% achieved blastocyst stage at day 5. In the rFSH group, these values were, respectively, 86% and 52%. Fertilized MII oocytes (*n* = 23 in the HP-hMG and *n* = 61 in the rFSH group) were divided into oocytes that developed into (i) top/good quality (52% in the HP-hMG and 70% in the rFSH group, no significant difference (*ε* = 1.65)) or poor quality embryos at day 3; and then into (ii) good (AA and AB) (43% for the HP-hMG and 29% for the rFSH group, no significant difference (*ε* = 1.28)) or bad grade (AC, BC, CC, and CB) blastocysts at day 5 ([Figure 1](#fig1){ref-type="fig"}). Then, the transcription profile of the cumulus cell samples isolated from these 101 MII oocytes was evaluated relative to day 3 embryo quality and blastocyst grading at day 5. In the HP-hMG group, *NPY1R*(x1.58, FDR = 0.0004) and *NPY2R* (x1.67, FDR = 0.0004) upregulation was observed in CCs isolated from MII oocytes that developed into top/good day 3 embryos, whereas *GM2A* (x2.10, FDR = 0.0005) and *USP45* (x2.32, FDR = 0.0005) were upregulated in cumulus cells from MII oocytes with good blastocyst grading ([Figure 3(a)](#fig3){ref-type="fig"}). After rFSH treatment, upregulation of *GREM1* (x1.59, FDR = 0) and *PSPH*(x1.6, FDR = 0) was significantly associated with top/good quality day 3 embryos; *OSBPL6*(x1.59, FDR = 0) upregulation was found in CCs from oocytes that developed into good blastocyst at day 5 ([Figure 3(b)](#fig3){ref-type="fig"}). In the two gonadotropin groups, *PTX3*(x-1.81, FDR = 0) downregulation and *STC2* (x1.76, FDR = 0) upregulation were observed in CCs isolated from MII oocytes that developed into top/good day 3 embryos, whereas *TRIM65* (x-1.62, FDR = 0) and *GSTM2* (x-1.67, FDR = 0) expressions were downregulated in CCs associated with good blastocyst grading ([Figure 3(c)](#fig3){ref-type="fig"}).

3.4. CC mRNA Content and **In Vitro** Blastocyst Outcome at Day 5 {#sec3.4}
-----------------------------------------------------------------

Independently of the type of gonadotropin treatment used, the relation between amplified mRNA content of CC samples and *in vitro* blastocyst development at day 5 was also investigated. Seventeen CC samples, isolated from MII oocytes that developed into top quality 8-cell embryos at day 3, were selected and divided in three groups: (i) CCs from MII oocytes that developed into good quality (grade AA-AB, *n* = 7), (ii) intermediary (grade BB, *n* = 6), and (iii) bad (grade CC and others, *n* = 4) blastocysts. The amount (mean ± SEM) of amplified mRNA from CCs from MII oocytes leading to good quality blastocysts was 1044.28 ± 159.18 ng/*μ*L. This value decreased to 796.66 ± 150 ng/*μ*L in the intermediary group and to 627.50 ± 76.25 ng/*μ*L in the bad blastocyst grade group ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Following global genomic assessment of 146 human CCs transcriptome under HP-hMG and rFSH treatments, the present study revealed a small but significant distinct molecular signature of 94 genes between the two treatments, suggesting that these treatments impact differentially the CC gene expression profile. This may be accounted for by the differences in the origin of the two pharmaceutical preparations. More precisely, overexpression of genes involved in the metabolism of lipids such as *GM2A*, *AKR1C1* and *AKR1C2*, as well as genes related to the intercellular signaling (*GJA5* and *FOS*) was observed in the CCs treated with HP-hMG, while genes involved in "cellular assembly and organization" (*COL1A1*, *COL3A1*, *MT3*, *TNFAIP6*, and*TNFAIP8*) were overexpressed in the rFSH CCs. Each of these functions plays a central role in oocyte maturation and/or oocyte competence \[[@B31]--[@B33]\]. Indeed, the metabolism of lipids represents the main energy source for protein synthesis during oocyte nuclear maturation and early embryo development \[[@B34], [@B35]\]. Simultaneously, adequate communication between oocyte and CCs and appropriate assembly and organization of the CC matrix are required for both oocyte maturation and competence \[[@B36]--[@B38]\]. Most of the genes, identified in the present investigation as differentially expressed in CCs treated with HP-hMG and rFSH, were reported for the first time, except for *TNFAIP6*and *GJA5* (connexin 40) which have been previously identified as potential markers of oocyte competence in CCs from bovine preovulatory follicles \[[@B39]\] and biomarker of oocyte maturation in canine cumulus-oocyte complexes matured *in vitro*, respectively \[[@B38]\].

Furthermore, the comparison of our data with the two other transcriptomic studies comparing the same gonadotropin treatment in granulosa cells (GCs) using the GnRH agonist long protocols \[[@B24], [@B25]\] indicates that *GM2* ganglioside activator is upregulated in HP-hMG CCs (this study) and rFSH GCs \[[@B24]\]. *GM2A* is known to play an important role in the hydrolysis of phospholipids or small glycolipids \[[@B40]\]. In addition, among the 9 common genes of our study and the one by Brannian et al. \[[@B25]\], six genes (*ATP7A*, *BTRC*, *LRRN3*, *STRN3*, *PTER*, and *SUPT3*) are upregulated in both CCs and GCs after rFSH treatment; one (*H19*) was upregulated in both rFSH CCs and HP-hMG GCs and the two others (*SERPINI1* and *SSFA2*) in HP-hMG CCs and rFSH. The use of different GnRH analogs might explain these discrepancies, but we cannot exclude the possibility that gonadotropin stimulation might have different effects on CCs and GCs. More investigations are required to address this issue.

On the other hand, we reported an important common CC molecular signature revealing the preservation of numerous growth factor signaling between the two types of treatments including the *IGF*, *PDGF*, *FGF*, and *EGF* pathways (See Figure SIII). These signaling pathways have been previously reported to play a central role in the control of the intrafollicular androgen/estrogen ratio for the *IGF* members \[[@B41]\], in angiogenesis and embryo development for the *FGF* and *PDGF* members \[[@B42]\] and in oocyte maturation for the members of the *EGF* family \[[@B43]--[@B45]\]. The interactions between these signaling pathways in CCs under COS will be a precious itinerary to explore in future works in order to complete the oocyte competence puzzle.

Another important finding of this study is that the mRNA level for key genes involved in ovulation process including hormonal receptors (*LHCGR* and *BMPR2*) and regulators of steroidogenesis (*StAR*, *HSD3B2*, *Activins*, and *Inhibins*) was comparable in the HP-hMG and rFSH CC groups. This suggests a similar potency of the two protocols to induce hormonal receptors and similar estrogenic capacity of the CC samples stimulated by HP-hMG and rFSH. This is in line with several studies reporting that CCs *in vitro* were able to secrete estradiol during COCs culture from patients undergoing stimulated cycles, probably as a consequence of the action of gonadotropins \[[@B46]\].

We also identified a significant relationship between some CC genes that were specifically upregulated following stimulation with HP-hMG or rFSH and *in vitro* embryo development. In the HP-hMG group, upregulation of *NPY1R* and *NPY2R* in CCs was associated with top/good embryo quality at day 3. *NPY* modulates steroid production through *NPY* receptors \[[@B47]\] and plays a role in human ovarian steroidogenesis directly at the level of the granulosa cells of the follicles in the early stage of luteinization \[[@B48], [@B49]\]. Additionally, the association of ubiquitin specific protease 45 (*USP45*) with good blastocyst quality suggests the requirement of proteasomal activity in HP-hMG-treated CCs. Proteasomal activity has been reported to have multiple functions in CCs expansion, in oocyte meiosis, and in the modification of cumulus-oocyte communication \[[@B50]\].

In the rFSH group, upregulation of gremlin 1 (*GREM1*) in CCs was associated with top/good embryo quality at day 3 and *OSBPL6* upregulation with good blastocyst grading at day 5. Only CC expression of *GREM1*, a member of the bone morphogenic protein (*BMP*) antagonist family, has been reported as positively correlated with embryo quality \[[@B7], [@B12], [@B51]\]. The regulation of *BMP* through *GREM1* is thought to contribute to CCs expansion and therefore to the final maturation of oocytes \[[@B52]\]. The gene *OSBPL6* codes for the oxysterol binding protein-like-6 receptor. Oxysterols, which bind to this receptor, are potent modulators of expression of cholesterol synthesis in human granulosa cells \[[@B53]\]. Recently, Watanabe et al. \[[@B54]\] reported that variation in cholesterol contents in cumulus-oocyte complexes during *in vitro* maturation of porcine oocytes affected their ability to be fertilized, suggesting that, under rFSH regime, cholesterogenesis at a nearby site of oocyte growth and maturation might also be involved in *in vitro* blastocyst outcome.

On the other hand, we also identified CC genes associated with day 3 embryo quality and blastocyst grading at day 5, independently of the type of gonadotropins. Among these genes, we report for the first time the expression of *STC2*, *GSTM2*, and *TRIM65*, as well as *PTX3* which has been shown in previous studies to either be associated with fertilization rate \[[@B55]\] or to have no relationship with high-quality embryo on day 3 \[[@B51]\]. A possible reason for higher stanniocalcin 2 (*STC2*) expression in the CCs isolated from MII oocytes that developed into top/good day 3 is the modulation of the angiogenic \[[@B56]\] or steroidogentic pathways \[[@B57]\] or principal processes in ovarian function \[[@B58]--[@B60]\]. Conversely, we observed an increased expression of *GSTM2*and *TRIM65* in CCs from oocytes that developed into bad blastocyst grading. *GSTM2* and *TRIM65* play a role in the protection against lipid peroxidation \[[@B61]\] and in DNA repair \[[@B62]\] respectively, suggesting an increase in cellular resistance against oxidative stress and damaged DNA. The implications of these genes, at the CC level, deserve to be addressed in future studies in order to understand their function in follicular growth.

Furthermore, independently of the type of gonadotropin treatment, we found an association between blastocyst grading at day 5 and the amount of amplified mRNA in CC samples from MII mature oocytes with comparable top/good embryo quality at day 3. Lower mRNA values were detected in CCs from MII oocytes that developed into bad blastocysts as compared to CC samples from oocytes that developed into intermediary or good quality blastocysts at day 5. This suggests that CCs surrounding an incompetent oocyte are less transcriptionally active.

These results are in line with our previously published data showing a general reduction in transcriptomic activity of CCs associated with poor oocyte competence and negative clinical outcome \[[@B6]\].

5. Conclusion {#sec5}
=============

Analysis of the microarray data of CCs from patients, who underwent GnRH-antagonist COS, highlights a significant difference in the gene expression profile of CCs following treatment with HP-hMG or rFSH. Components of signaling pathways (the *EGF*, *IGF*, *FGF*, and *PDGF* cascades) were conserved in CCs under the two gonadotropin stimulation regimens. Some genes specific to each gonadotropin treatment or commonly expressed in both groups were associated with *in vitro* embryo development. Moreover, independently of the gonadotropin preparation used, the amount of amplified mRNA in each CC was associated with blastocyst grading at day 5. These genes may prove valuable as biomarkers of *in vitro* embryo quality and can be useful for understanding the biology of stimulation.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Material available online includes: (i) Baseline clinical characteristics, end-of-stimulation data and number of oocytes retrieved from each patient following controlled ovarian stimulation with HP-hMG or rFSH. (ii) Primer pairs used for validation of the array data by qRT-PCR. (iii) List of the 9,805 common genes expressed in both HP-hMG and rFSH CC samples. (iv) Validation by qRT-PCR of some of the genes that were differentially expressed in HP-hMG and rFSH CC samples. (v) Top-ranked networks evidenced in common HP-hMG/rFSH signature by Ingenuity Pathway software. (vi) Detailed list of the genes presented in the network. (vii) The major signaling pathways that occur in CCs following the gonadotropin (HP-hMG and rFSH) stimulation.

###### 

Click here for additional data file.
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![Distribution tree of cumulus cell (CC) samples and embryo outcome relative to the used COS protocol.](BMRI2013-354582.001){#fig1}

![Gene expression patterns of the HP-hMG and rFSH CC samples. Supervised hierarchical clustering of CC samples based on the 94 genes that are differentially expressed between the two treatment groups (HP-hMG and rFSH). We can see a distinct signature in each CCs category. The color intensity indicates the level of gene expression (red for upregulated genes and green for downregulated genes).](BMRI2013-354582.002){#fig2}

![Gonadotropin gene expression associated with *in vitro* embryo development. (a) and (b) Box-and-whisker plots comparing the expression level of gonadotropin-specific gene in CCs from oocytes that developed into top/good quality embryos (*n* = 43 in the rFSH and *n* = 12 in the HP-hMG group) or poor quality embryos (*n* = 16 in the rFSH and *n* = 11 in the HP-hMG group) and into good blastocysts (*n* = 18 in the rFSH and *n* = 10 in the HP-hMG group) or bad blastocysts (*n* = 14 in the rFSH and *n* = 4 in the HP-hMG group). (c) Box-and-whisker plots comparing the expression level of gonadotropin common genes in CCs from oocytes that developed into top/good quality embryos (*n* = 55 CCs) or poor quality embryos (*n* = 27 CCs) and into good blastocysts (*n* = 28 CCs) or bad blastocysts (*n* = 18 CCs). The signal intensity for each gene is shown on the *y*-axis as arbitrary units determined by the Affymetrix GCOS software. \*A significant difference with FDR ≤0.05.](BMRI2013-354582.003){#fig3}

![Relationship between amount of amplified CCs mRNA and blastocyst quality. Three groups of blastocysts (good, intermediary, or bad quality) were obtained from top and good 8-cell embryos at day 3. The Kruskal-Wallis test was used to indicate that at least one of the groups is different from the others (*P* = 0.011, Kruskal-Wallis test), and the Wilcoxon test was used to establish whether group AA-AB is significantly different from group BB and/or group CC. \*A significant difference in the concentration of amplified CC mRNA between two groups of blastocysts. CC samples (*n* = 17) were from oocytes that developed in top and good 8-cell embryos at day 3. AA-AB: good blastocyst grades (*n* = 7); BB: intermediary blastocyst grades (*n* = 6); CC and others: bad blastocyst grades (*n* = 4). Bars represent the mean ± SEM.](BMRI2013-354582.004){#fig4}

###### 

List of genes that were significantly upregulated in HP-hMG CCs compared with rFSH CCs.

  Gene name   Gene title                                                                                             Probesets       Fold change   FDR (%)
  ----------- ------------------------------------------------------------------------------------------------------ --------------- ------------- ---------
  PHACTR2     Phosphatase and actin regulator 2                                                                      244774_at       2.9           0
  GM2A        GM2 ganglioside activator                                                                              235678_at       2.3           0
  LOC654433   *Homo sapiens*, clone IMAGE:4826696, mRNA                                                              228425_at       2.2           0
  LOC201651   Similar to esterase/N-deacetylase (EC 3.5.1.-), 50 K hepatic-rabbit                                    1569582_at      2.1           0
  PAX8        Transcribed locus, moderately similar to XP_375099.1 hypothetical protein LOC283585 (*Homo sapiens*)   227474_at       2.1           0
  NPY1R       Neuropeptide Y receptor Y1                                                                             205440_s\_at    2.1           0
  GJA5        Gap junction protein, alpha 5, 40 kDa (connexin 40)                                                    226701_at       1.9           0
  FOXG1B      Forkhead box G1B                                                                                       206018_at       1.9           0
  SPP1        Secreted phosphoprotein 1                                                                              209875_s\_at    1.9           0.58
  NTS         Neurotensin                                                                                            206291_at       1.8           0.58
  THAP4       THAP domain containing 4                                                                               220417_s\_at    1.8           0
  SPESP1      Sperm equatorial segment protein 1                                                                     229352_at       1.8           0.58
  SEMA6D      Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D                        233882_s\_at    1.8           0.58
  DOCK8       Dedicator of cytokinesis 8                                                                             225502_at       1.8           0.58
  SERPINB2    Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2                               204614_at       1.7           0.58
  PPP1R14C    Protein phosphatase 1, regulatory (inhibitor) subunit 14C                                              226907_at       1.7           0
  CTIF        CBP80/20-dependent translation initiation factor                                                       243090_at       1.7           0
  SSFA2       Sperm-specific antigen 2                                                                               236207_at       1.7           0
  HS3ST1      Heparan sulfate (glucosamine) 3-O-sulfotransferase 1                                                   205466_s\_at    1.7           0
  CYP1B1      Cytochrome P450, family 1, subfamily B, polypeptide 1                                                  202437_s\_at    1.7           0
  TMEM37      Transmembrane protein 37                                                                               1554485_s\_at   1.6           0
  BBS12       Hypothetical protein FLJ35630                                                                          229603_at       1.6           0
  AKR1C2      Aldo-keto reductase family 1, member C2                                                                211653_x\_at    1.6           0.58
  MALL        BENE protein                                                                                           209373_at       1.6           0
  NPY2R       Neuropeptide Y receptor Y2                                                                             210729_at       1.6           0
  METTL7B     Hypothetical protein MGC17301                                                                          227055_at       1.6           0
  RNF128      Ring finger protein 128                                                                                219263_at       1.6           0
  ARL4C       ADP-ribosylation factor-like 7                                                                         202207_at       1.6           0
  PAPPA       Pregnancy-associated plasma protein A, pappalysin 1                                                    240450_at       1.6           0
  USP45       Ubiquitin-specific protease 45                                                                         224441_s\_at    1.6           0
  FOS         v-fos FBJ murine osteosarcoma viral oncogene homolog                                                   209189_at       1.6           0
  PDK4        Pyruvate dehydrogenase kinase, isozyme 4                                                               225207_at       1.6           0
  ZNF718      Hypothetical protein FLJ90036                                                                          1553269_at      1.6           0
  ARHGAP20    Rho GTPase activating protein 20                                                                       228368_at       1.5           0
  FLJ43663    CDNA FLJ26188 fis, clone ADG04821                                                                      238619_at       1.5           0
  HOP         Homeodomain-only protein                                                                               211597_s\_at    1.5           0
  ENPP2       Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)                                         209392_at       1.5           2.95
  LYZ         Lysozyme (renal amyloidosis)                                                                           213975_s\_at    1.5           1.05
  SKAP2       src family associated phosphoprotein 2                                                                 204361_s\_at    1.5           0
  ABHD12      Chromosome 20 open reading frame 22                                                                    228124_at       1.5           0
  RUNX1       Runt-related transcription factor 1                                                                    236114_at       1.5           0
  AKR1C1      Aldo-keto reductase family 1, member C2                                                                216594_x\_at    1.5           0
  BRE         Brain and reproductiveorgan-expressed(TNFRSF1A modulator)                                              211566_x\_at    1.5           0
  SERPINI1    Serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1                             205352_at       1.5           0
  RASL11B     RAS-like, family 11, member B                                                                          219142_at       1.5           0

###### 

List of genes that were significantly upregulated in rFSH CCs compared with HP-hMG CCs.

  Gene name      Gene title                                                                                Probesets       Fold change   FDR (%)
  -------------- ----------------------------------------------------------------------------------------- --------------- ------------- ---------
  ITM2A          Integral membrane protein 2A                                                              202746_at       4.2           0
  H19            H19, imprinted maternally expressed transcript (nonprotein coding)                        224646_x\_at    3.8           0
  PSPH           Phosphoserine phosphatase                                                                 205048_s\_at    2.4           0
  GAL            Galanin                                                                                   214240_at       2.4           0
  ZNF528         Zinc finger-like                                                                          232315_at       2.3           0
  NFKBIZ         Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, zeta         223217_s\_at    2.2           4.73
  FAM84B         Breast cancer membrane protein 101                                                        225864_at       2             0
  COL3A1         Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)          211161_s\_at    2             1.53
  DKFZp451A211   DKFZp451A211 protein                                                                      1556114_a\_at   1.8           0
  SPARCL1        SPARC-like 1 (mast9, hevin)                                                               200795_at       1.8           0
  PTER           Phosphotriesterase related                                                                222798_at       1.8           0
  NFIB           Nuclear factor I/B                                                                        213032_at       1.8           0
  MXRA5          Adlican                                                                                   209596_at       1.8           0
  GALNTL2        UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 2   228501_at       1.8           0
  SUPT3H         Suppressor of Ty 3 homolog (*S*. cerevisiae)                                              211106_at       1.7           0
  DDX17          DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 /// DEAD (Asp-Glu-Ala-Asp) box polypeptide 17   208151_x\_at    1.7           4.15
  TNFAIP6        Tumor necrosis factor, alpha-induced protein 6                                            206026_s\_at    1.7           1.05
  MTUS1          Mitochondrial tumor suppressor 1                                                          212096_s\_at    1.7           4.73
  RP1-93H18.5    Similar to RIKEN cDNA A630077B13 gene, RIKEN cDNA 2810048G17                              229390_at       1.7           0
  LOC92196       Hypothetical LOC92196 (uncharacterized)                                                   229290_at       1.6           0
  LOC401317      Hypothetical LOC402472 (uncharacterized)                                                  242329_at       1.6           0
  CHAC1          Hypothetical protein MGC4504                                                              219270_at       1.6           0
  STRN3          Striatin, calmodulin binding protein 3                                                    215505_s\_at    1.6           0
  OSBPL10        Oxysterol binding protein-like 10                                                         219073_s\_at    1.6           0
  GLIPR1         HIV-1 rev binding protein 2                                                               214085_x\_at    1.6           0
  BTRC           Beta-transducin repeat containing E3 ubiquitin protein ligase                             237862_at       1.6           0
  TNFAIP8        Tumor necrosis factor, alpha-induced protein 8                                            208296_x\_at    1.6           0.54
  PMAIP1         Phorbol-12-myristate-13-acetate-induced protein 1                                         204286_s\_at    1.6           0
  RBM24          RNA binding motif protein 24                                                              235004_at       1.6           1.53
  LOC388796      Hypothetical LOC388796 (uncharacterized)                                                  65588_at        1.6           0
  LOC157278      *Homo sapiens*, clone IMAGE:5285282, mRNA (uncharacterized)                               238716_at       1.6           0
  GREM1          Gremlin 1                                                                                 218468_s\_at    1.6           0
  OSBPL6         Oxysterol binding protein-like 6                                                          223805_at       1.6           0
  CREB5          cAMP responsive element binding protein 5                                                 205931_s\_at    1.5           0
  CAMK1D         Calcium/calmodulin-dependent protein kinase ID                                            235626_at       1.5           0
  CCDC58         Hypothetical LOC131076                                                                    235244_at       1.5           0
  LRRN3          Leucine-rich repeat neuronal 3                                                            209840_s\_at    1.5           0
  HS3ST3A1       Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1                                    219985_at       1.5           0
  ARSD           Arylsulfatase D                                                                           232423_at       1.5           0
  ENDOD1         KIAA0830 protein                                                                          212570_at       1.5           0
  ZNF521         Zinc finger protein 521                                                                   226676_at       1.5           0
  DFNA5          Deafness, autosomal dominant 5                                                            203695_s\_at    1.5           0
  PSD3           Pleckstrin and Sec7 domain containing 3                                                   203354_s\_at    1.5           0
  LOC283070      Hypothetical protein LOC283070 (uncharacterized)                                          226382_at       1.5           0
  COL1A1         Collagen, type I, alpha 1                                                                 1556499_s\_at   1.5           0
  SPOCK2         Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2                  202523_s\_at    1.5           0
  ATP7A          ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)                            205197_s\_at    1.5           0
  MT3            Metallothionein 3 (growth inhibitory factor (neurotrophic))                               205970_at       1.5           0
  DDIT3          DNA-damage-inducible transcript 3                                                         209383_at       1.5           0

[^1]: Academic Editor: Shivani Soni
